SlideShare una empresa de Scribd logo
1 de 1
Descargar para leer sin conexión
PRESS RELEASE (to be released Tuesday, 29 January 2013)

Evotec to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo | Monaco|
21-22 March 2013

marcus evans is pleased to announce the participation of Evotec as a Sponsor at the Discovery
Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013.

The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug
discovery sponsors to focus in an intimate environment on discussions around key new drivers
shaping discovery research and development today. More details about the Discovery Summit 2013
can be found here.

Evotec is a drug discovery alliance and development partnership company focused on rapidly
progressing innovative product approaches with leading pharmaceutical and biotechnology
companies. We operate worldwide providing the highest quality stand-alone and integrated drug
discovery solutions, covering all activities from target-to-clinic. The Company has established a
unique position by assembling top-class scientific experts and integrating state-of-the-art
technologies as well as substantial experience and expertise in key therapeutic areas including
neuroscience, pain, metabolic diseases as well as oncology and inflammation. www.evotec.com

For further information on the Discovery Summit 2013 programme please contact
Ruth Abbott
Marketing PR & Communications Director
ruth.PRsummits@marcusevans.com
marcus evans

Más contenido relacionado

Más de Life Sciences Network marcus evans

Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Life Sciences Network marcus evans
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Life Sciences Network marcus evans
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...Life Sciences Network marcus evans
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Life Sciences Network marcus evans
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Life Sciences Network marcus evans
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Life Sciences Network marcus evans
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Life Sciences Network marcus evans
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Life Sciences Network marcus evans
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Life Sciences Network marcus evans
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Life Sciences Network marcus evans
 
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisCRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisLife Sciences Network marcus evans
 
Adopting a truly patient-centric strategy to find a cure for rare diseases
Adopting a truly patient-centric strategy to find a cure for rare diseasesAdopting a truly patient-centric strategy to find a cure for rare diseases
Adopting a truly patient-centric strategy to find a cure for rare diseasesLife Sciences Network marcus evans
 
The one-on-one meetings with potential customers is what matters most
The one-on-one meetings with potential customers is what matters mostThe one-on-one meetings with potential customers is what matters most
The one-on-one meetings with potential customers is what matters mostLife Sciences Network marcus evans
 
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...Life Sciences Network marcus evans
 
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...Achieving Realistic Project Timelines through Strategic Partnerships and Alli...
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...Life Sciences Network marcus evans
 

Más de Life Sciences Network marcus evans (20)

Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
 
Business Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENABusiness Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENA
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
 
Where marcus evans fits in our business development mix
Where marcus evans fits in our business development mixWhere marcus evans fits in our business development mix
Where marcus evans fits in our business development mix
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
 
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic RhinoconjunctivitisCRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
CRTH2 Antagonists for the Treatment of Asthma and Allergic Rhinoconjunctivitis
 
Grow Your Business
Grow Your BusinessGrow Your Business
Grow Your Business
 
What it Takes to Achieve a Successful Drug Discovery Alliance
What it Takes to Achieve a Successful Drug Discovery AllianceWhat it Takes to Achieve a Successful Drug Discovery Alliance
What it Takes to Achieve a Successful Drug Discovery Alliance
 
Adopting a truly patient-centric strategy to find a cure for rare diseases
Adopting a truly patient-centric strategy to find a cure for rare diseasesAdopting a truly patient-centric strategy to find a cure for rare diseases
Adopting a truly patient-centric strategy to find a cure for rare diseases
 
The one-on-one meetings with potential customers is what matters most
The one-on-one meetings with potential customers is what matters mostThe one-on-one meetings with potential customers is what matters most
The one-on-one meetings with potential customers is what matters most
 
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
 
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...Achieving Realistic Project Timelines through Strategic Partnerships and Alli...
Achieving Realistic Project Timelines through Strategic Partnerships and Alli...
 

Evotec to join the Discovery Summit 2013 at Le Méridien Beach Plaza, Monte-Carlo, Monaco, 21-22 March 2013

  • 1. PRESS RELEASE (to be released Tuesday, 29 January 2013) Evotec to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo | Monaco| 21-22 March 2013 marcus evans is pleased to announce the participation of Evotec as a Sponsor at the Discovery Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013. The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug discovery sponsors to focus in an intimate environment on discussions around key new drivers shaping discovery research and development today. More details about the Discovery Summit 2013 can be found here. Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. www.evotec.com For further information on the Discovery Summit 2013 programme please contact Ruth Abbott Marketing PR & Communications Director ruth.PRsummits@marcusevans.com marcus evans